The influence of multimodal behavioral treatment on theconsumption of acute migraine drugs: a randomized, controlled study
2012 (English)In: Cephalalgia, ISSN 0333-1024, E-ISSN 1468-2982, Vol. 32, no 4, 297-307 p.Article in journal (Other academic) Published
Objectives: To characterize overall drug use in migraine in conjunction with multimodal behavioral treatment.
Methods: 76 adults reporting at least two monthly migraine attacks underwent a randomized, controlled 24-week multimodal behavioral treatment intervention. Migraine drugs and symptoms were registered in an Internet-based diary.
Results: During 4256 days of baseline registration, 859 drug doses were taken during 655 of the 856 days with migraine headache. Triptans and analgesics constituted 56.7 and 38.3 percent of all doses with efficacy ratios of 0.41, and 0.20, respectively. Men displayed significantly lower drug efficacy (p = 0.001) and used triptans significantly less (p < 0.001) and analgesics significantly more (p < 0.001) than women did. At the end of multimodal behavioral treatment, total drug consumption decreased by 22 percent (p = 0.021), corresponding to 27 percent fewer days with migraine headache. Drug efficacy increased during multimodal behavioral treatment from 0.30 to 0.52 (p < 0.001), mainly explained by an increased proportion of mild attacks which also was the attack category which displayed the largest increase in drug efficacy.
Conclusions: Triptans were the most used and efficient drugs. Multimodal behavioral treatment led to decreased and more efficient drug consumption. Men used triptans less frequently.
Place, publisher, year, edition, pages
2012. Vol. 32, no 4, 297-307 p.
Migraine, medication, multimodal behavioral treatment, gender, drug use, drug efficacy
Research subject Neurology
IdentifiersURN: urn:nbn:se:uu:diva-157979DOI: 10.1177/0333102412437386ISI: 000301518200006OAI: oai:DiVA.org:uu-157979DiVA: diva2:437782